|Bid||185.75 x 1200|
|Ask||193.14 x 1200|
|Day's Range||185.64 - 189.17|
|52 Week Range||185.64 - 306.08|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||17.95|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||262.90|
Star investor Cathie Wood is usually one to follow. In less than a year, the biotech company ended development of two candidates in one of its rare-disease programs. Now the question is, should you follow Wood's lead and consider shares of this biotech company?
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Sometimes a potential drug or treatment may seem like a failure, but can still be salvaged for researchers' use. That is the case with Vertex Pharmaceuticals Inc.'s (VRTX) VX-864 for Alpha-1 Antitrypsin Deficiency (AATD). In its June 10 update to investors, the company announced that it will not be moving the drug to late-stage development. (See VRTX stock analysis on TipRanks) Five-star analyst Hartaj Singh of Oppenheimer & Co. covered the stock in his report, optimistically stating that the fa